FDA approves tafasitamab with lenalidomide and rituximab, offering a groundbreaking chemotherapy-free treatment for relapsed ...

FDA updates CAR T-cell therapy labels for liso-cel and ide-cel, easing monitoring requirements and expanding access for ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Panelists discuss how to approach a 67-year-old man with advanced polycythemia vera who is resistant to hydroxyurea, ...

Despite major advances, real-world data show diminishing survival outcomes and treatment-limiting toxicities in second line ...

During a live event, Jeffrey V. Matous, MD, discussed flexible dosing and the need to expand use in community practices for ...

A recent trial reveals that nivolumab combined with chemotherapy significantly improves survival rates in older patients with ...

Surbhi Sidana, MD, discusses updates from the CARTITUDE-4 study assessing the CAR T therapy cilta-cel in patients with ...

Detalimogene voraplasmid gains FDA RMAT designation, showcasing a 71% response rate in treating high-risk, BCG-unresponsive ...

A panelist discusses how patients with advanced cGVHD often cycle through multiple approved agents over time due to ...

Discover how data analytics transforms health care by reducing costs, improving patient outcomes, and enhancing operational ...

New study reveals mosunetuzumab and polatuzumab vedotin significantly improve outcomes for patients with relapsed large ...